SAGE THERAPEUTICS INC (SAGE) Stock Price, Quote, News and Overview
NASDAQ:SAGE - Nasdaq - US78667J1088 - Common Stock - Currency: USD
SAGE Quote, Performance and Key Statistics
7.79
+0.17 (+2.23%)
The current stock price of SAGE is 7.79 USD. In the past month the price decreased by -9.42%. In the past year, price decreased by -43.1%.
SAGE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.82 | 319.07B | ||
| AMGN | AMGEN INC | 14.12 | 150.46B | ||
| GILD | GILEAD SCIENCES INC | 23.03 | 132.33B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1698.17 | 126.60B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.14 | 65.57B | ||
| ARGX | ARGENX SE - ADR | 322.85 | 36.67B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.56B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.98B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.60B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 27.06B | ||
| NTRA | NATERA INC | N/A | 20.88B | ||
| BIIB | BIOGEN INC | 7.26 | 17.49B |
Related stock screener links
About SAGE
Company Profile
SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 353 full-time employees. The company went IPO on 2014-07-18. The firm has developed two FDA-approved treatments indicated for postpartum depression (PPD) and is advancing a portfolio of internally discovered novel chemical entities with the potential to become differentiated treatments designed to improve brain health by primarily targeting two critical central nervous system, receptor systems, GABA and NMDA. Its product ZURZUVAE is for the treatment of PPD in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, and is the first oral, once-daily, 14-day treatment specifically indicated for adults with PPD. The company is also evaluating potential indications for SAGE-324, a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing, including seizures in developmental and epileptic encephalopathies. Its other areas of focus are SAGE-319, SAGE-039, and SAGE-817.
Company Info
SAGE THERAPEUTICS INC
215 1st St
Cambridge MASSACHUSETTS 02142 US
CEO: Barry E. Greene
Employees: 487
Company Website: https://www.sagerx.com/
Investor Relations: https://investor.sagerx.com/
Phone: 16172998380
SAGE THERAPEUTICS INC / SAGE FAQ
What is the stock price of SAGE THERAPEUTICS INC today?
The current stock price of SAGE is 7.79 USD. The price increased by 2.23% in the last trading session.
What is the ticker symbol for SAGE THERAPEUTICS INC stock?
The exchange symbol of SAGE THERAPEUTICS INC is SAGE and it is listed on the Nasdaq exchange.
On which exchange is SAGE stock listed?
SAGE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SAGE THERAPEUTICS INC stock?
25 analysts have analysed SAGE and the average price target is 8.15 USD. This implies a price increase of 4.62% is expected in the next year compared to the current price of 7.79. Check the SAGE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SAGE THERAPEUTICS INC worth?
SAGE THERAPEUTICS INC (SAGE) has a market capitalization of 478.93M USD. This makes SAGE a Small Cap stock.
How many employees does SAGE THERAPEUTICS INC have?
SAGE THERAPEUTICS INC (SAGE) currently has 487 employees.
What are the support and resistance levels for SAGE THERAPEUTICS INC (SAGE) stock?
SAGE THERAPEUTICS INC (SAGE) has a support level at 7.52 and a resistance level at 7.83. Check the full technical report for a detailed analysis of SAGE support and resistance levels.
Is SAGE THERAPEUTICS INC (SAGE) expected to grow?
The Revenue of SAGE THERAPEUTICS INC (SAGE) is expected to grow by 90.29% in the next year. Check the estimates tab for more information on the SAGE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SAGE THERAPEUTICS INC (SAGE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SAGE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SAGE, evaluating the profitability, health, valuation and growth aspects
- SAGE THERAPEUTICS INC (SAGE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SAGE THERAPEUTICS INC (SAGE) Sales and EPS estimates to see what analysts future expectations are.
- SAGE THERAPEUTICS INC (SAGE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SAGE THERAPEUTICS INC (SAGE) Insider and Institutional Ownership to learn about the owners and their transactions.
- SAGE THERAPEUTICS INC (SAGE) Stock Chart to make your own analysis
- SAGE THERAPEUTICS INC (SAGE) Latest news and press-releases to stay up to date.
Does SAGE THERAPEUTICS INC (SAGE) stock pay dividends?
SAGE does not pay a dividend.
When does SAGE THERAPEUTICS INC (SAGE) report earnings?
SAGE THERAPEUTICS INC (SAGE) will report earnings on 2025-04-29, before the market open.
What is the Price/Earnings (PE) ratio of SAGE THERAPEUTICS INC (SAGE)?
SAGE THERAPEUTICS INC (SAGE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.59).
What is the Short Interest ratio of SAGE THERAPEUTICS INC (SAGE) stock?
The outstanding short interest for SAGE THERAPEUTICS INC (SAGE) is 7.24% of its float. Check the ownership tab for more information on the SAGE short interest.
SAGE Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to SAGE. When comparing the yearly performance of all stocks, SAGE is a bad performer in the overall market: 74.06% of all stocks are doing better.
SAGE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SAGE. The financial health of SAGE is average, but there are quite some concerns on its profitability.
SAGE Financial Highlights
Over the last trailing twelve months SAGE reported a non-GAAP Earnings per Share(EPS) of -6.59. The EPS increased by 36.08% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -73.22% | ||
| ROE | -86.15% | ||
| Debt/Equity | 0 |
SAGE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 67% to SAGE. The Buy consensus is the average rating of analysts ratings from 25 analysts.
For the next year, analysts expect an EPS growth of 45.65% and a revenue growth 90.29% for SAGE